AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 600mg/sqm iv day 1 q21 days for four coursess
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 600mg/sqm iv day 1 q21 days for four coursess
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidoxorubicin
Description: 75mg/sqm iv day 1 q21 days for four courses
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidoxorubicin
Description: 75mg/sqm iv day 1 q21 days for four courses
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600mg/sqm day 1 q21 days for four courses
Study NCT00429299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600mg/sqm day 1 q21 days for four courses
Study NCT04472741 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: difference between colonoscopes
Description: patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff
Study NCT04241731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM 6000 IU/m2/dose Days 2 and 9
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 60 mg/m2/dose on Day 1
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
Study NCT04241731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
Study NCT00635284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: nab-rapamycin
Study NCT00726557 — intervention group
Intervention type: BIOLOGICAL
Intervention: PegIntron (pegylated interferon alfa-2b; SCH 54031)
Description: PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
Study NCT03818581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT03818581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT00840281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil® 500 mg tablets
Description: 1 x 500 mg, single-dose fasting
Study NCT00840281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg Tablets
Description: 1 x 500 mg, single-dose fasting
Study NCT00734019 — intervention group
Intervention type: DEVICE
Intervention: P.F.C. Sigma Knee
Description: Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
Study NCT03820427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: impulse oscillometry
Description: impulse oscillometry
Study NCT03820427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout test
Description: multiple breath washout test
Study NCT03820427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: body plethysmography
Study NCT02354560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
Study NCT01305681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LoFric® catheters during clean intermittent catheterization
Description: LoFric® catheters during clean intermittent catheterization
Study NCT03142165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: 3 weekly doses of 90 mg infused intravenous administration
Study NCT03142165 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03142165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg intravenous administration
Study NCT03142165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: 50 mg intravenous administration
Study NCT03142165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 20 mg intravenous administration
Study NCT03142165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Famotidine
Description: 20 mg intravenous administration
Study NCT01997372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) >1×109/L.
Study NCT01268787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
Study NCT01268787 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 vaccine
Description: Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
Study NCT00726557 — intervention group
Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO or IV 40 mg/m2/day on Days 1-28
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
Study NCT02582177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canesten®
Description: Apply on the affected area and around it twice a day
Study NCT04161768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norfloxacin 400 mg daily
Study NCT04161768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Description: Norfloxacin 400 mg daily
Study NCT04161768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride
Description: Itopride 50 mg three times daily
Study NCT04518956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inter maxillary fixation with shockwave therapy
Description: Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.
Study NCT04518956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inter maxillary fixation and exposure to low intensity pulsed
Description: Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.
Study NCT04518956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inter maxillary fixation
Description: Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
Study NCT04550013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy-Slow Resistance training
Description: Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).
Study NCT04550013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Load Blood Flow Restriction training
Description: Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
Study NCT02124122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Probiotic
Study NCT02124122 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02895763 — intervention group
Intervention type: OTHER
Intervention: Form administrations
Study NCT02193893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biological: Cell-based therapeutics
Description: Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
Study NCT03281135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HPV testing
Description: Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
Study NCT04542356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
Study NCT04542356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhG-CSF
Description: Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
Study NCT03977129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QFR-guided strategy
Description: In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR > 0.80, then no CABG revascularization of target blood vessels will be carried out.
Study NCT03977129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAG-guided strategy
Description: In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
Study NCT04004676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 km time trial performance
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
Study NCT04004676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 20 km time trial performance
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
Study NCT04004676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glycogen lowering exercise
Description: Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
Study NCT04004676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Glycogen lowering exercise
Description: Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
Study NCT00873093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
Study NCT00445445 — intervention group
Intervention type: OTHER
Intervention: physiologic testing
Description: Urine samples will be assessed for levels of bisphenol-A
Study NCT02193893 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Symptomatic treatment of ALS
Description: Symptomatic neurological treatment of ALS
Study NCT00445445 — intervention group
Intervention type: OTHER
Intervention: screening questionnaire administration
Description: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
Study NCT03988647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered at 200 mg IV every 3 weeks
Study NCT03988647 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 9 Gy X 3 (27 Gy in 3 fractions), or 4-6 Gy X 5 (20-30 Gy in 5 fractions).
Study NCT02057991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Watch an educational video
Study NCT02057991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAM exercise therapy
Description: Watch a mindfulness exercise video
Study NCT02057991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caregiver-related intervention or procedure
Description: Watch mindfulness exercise video and/or educational video
Study NCT02057991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02057991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00694343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (6%) in sodium chloride (solution for infusion)
Description: 500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
Study NCT00694343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate solution
Description: 1000 mL Ringer's Lactate solution
Study NCT04303923 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
Study NCT01120067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Treatment
Description: Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
Study NCT01120067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual.
Study NCT03761797 — intervention group
Intervention type: DRUG
Intervention: TRADIANCE® Combination Tablets AP
Description: Fixed dose combination
Study NCT03761797 — intervention group
Intervention type: DRUG
Intervention: TRADIANCE® Combination Tablets BP
Description: Fixed dose combination
Study NCT04032574 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Herbal Medicinal Product
Study NCT04032574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03872011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C,thiamine,hydrocortisone
Description: Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU.
Study NCT03872011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study NCT02739737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded manuscript
Description: Blinded version of sham manuscript
Study NCT02739737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unblinded manuscript
Description: Unblinded version of sham manuscript
Study NCT03120988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lavage with Platelet Poor Plasma (PPP)
Description: Lavage of 50cc PPP
Study NCT05245279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3 dimensional ultrasound investigation
Description: Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
Study NCT05245279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2 dimensional ultrasound investigation
Description: The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
Study NCT01551940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox injection
Description: Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
Study NCT01551940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
Study NCT00035347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV azithromycin
Description: 500 mg once daily
Study NCT00035347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: 1 gram once daily for 2 to 5 days
Study NCT00035347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azithromycin
Description: 2 x 250 mg once daily
Study NCT00035347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV levofloxacin
Description: 500 mg once daily
Study NCT00035347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral levofloxacin
Description: 500 mg once daily
Study NCT02919384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% oxygen concentration in the incubator
Description: At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6.